Quince Therapeutics (QNCX) director takes 29,423 options instead of 2026 cash retainer

Rhea-AI Filing Summary

Quince Therapeutics director David Lamond reported receiving a grant of 29,423 director stock options on January 2, 2026. The options have an exercise price of $3.00 per share and relate to Quince common stock, with 29,423 derivative securities beneficially owned after the transaction. According to the filing, these options were granted in lieu of Lamond’s 2026 annual director cash retainer under the company’s Outside Director Compensation Policy and will vest in equal quarterly installments over a one-year period. The transaction is reported as a directly held derivative security.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lamond David

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	29,423	$0.00	--

Holdings After Transaction: Director Stock Option (Right to Buy) — 29,423 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lamond David

(Last) (First) (Middle)

C/O QUINCE THERAPEUTICS, INC.

611 GATEWAY BLVD., SUITE 273

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Quince Therapeutics, Inc. [ QNCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$3	01/02/2026		A		29,423		(1)	01/02/2036	Common Stock	29,423	$0	29,423	D

Explanation of Responses:

1. The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy.

	/s/ Brendan Hannah as attorney-in-fact for David Lamond	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Quince Therapeutics (QNCX) report for David Lamond?

The filing reports that director David Lamond received 29,423 director stock options on January 2, 2026 as a derivative security award.

What are the key terms of David Lamond’s Quince Therapeutics (QNCX) stock options?

Lamond received 29,423 director stock options with an exercise price of $3.00 per share, each option relating to Quince common stock.

How do David Lamond’s 2026 director stock options vest at Quince Therapeutics (QNCX)?

The filing states that the 29,423 options will vest in equal quarterly installments over a one-year period.

Why did David Lamond receive stock options instead of cash from Quince Therapeutics (QNCX)?

According to the footnote, Lamond elected to receive stock options in lieu of the annual director cash retainer for 2026 under Quince’s Outside Director Compensation Policy.

How many Quince Therapeutics (QNCX) derivative securities does David Lamond hold after this transaction?

After the reported transaction, Lamond beneficially owns 29,423 director stock options, reported as direct ownership.

What type of security did David Lamond receive from Quince Therapeutics (QNCX)?

He received a Director Stock Option (Right to Buy), a derivative security giving him the right to purchase Quince common stock at a set price.